|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: POLR3F |
Gene summary for POLR3F |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | POLR3F | Gene ID | 10621 |
| Gene name | RNA polymerase III subunit F | |
| Gene Alias | C34 | |
| Cytomap | 20p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q05DB8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10621 | POLR3F | LZE4T | Human | Esophagus | ESCC | 7.06e-04 | 1.09e-01 | 0.0811 |
| 10621 | POLR3F | LZE24T | Human | Esophagus | ESCC | 3.17e-06 | 1.24e-01 | 0.0596 |
| 10621 | POLR3F | P2T-E | Human | Esophagus | ESCC | 9.33e-17 | 2.09e-01 | 0.1177 |
| 10621 | POLR3F | P4T-E | Human | Esophagus | ESCC | 4.59e-11 | 3.07e-01 | 0.1323 |
| 10621 | POLR3F | P5T-E | Human | Esophagus | ESCC | 3.52e-14 | 1.45e-01 | 0.1327 |
| 10621 | POLR3F | P8T-E | Human | Esophagus | ESCC | 2.35e-10 | 9.12e-02 | 0.0889 |
| 10621 | POLR3F | P9T-E | Human | Esophagus | ESCC | 2.90e-07 | 1.30e-01 | 0.1131 |
| 10621 | POLR3F | P10T-E | Human | Esophagus | ESCC | 2.70e-18 | 2.60e-01 | 0.116 |
| 10621 | POLR3F | P11T-E | Human | Esophagus | ESCC | 1.01e-10 | 4.33e-01 | 0.1426 |
| 10621 | POLR3F | P12T-E | Human | Esophagus | ESCC | 2.06e-14 | 2.15e-01 | 0.1122 |
| 10621 | POLR3F | P15T-E | Human | Esophagus | ESCC | 3.24e-08 | 1.98e-01 | 0.1149 |
| 10621 | POLR3F | P16T-E | Human | Esophagus | ESCC | 4.18e-16 | 2.57e-01 | 0.1153 |
| 10621 | POLR3F | P17T-E | Human | Esophagus | ESCC | 4.73e-05 | 1.74e-01 | 0.1278 |
| 10621 | POLR3F | P20T-E | Human | Esophagus | ESCC | 7.03e-06 | 1.57e-01 | 0.1124 |
| 10621 | POLR3F | P21T-E | Human | Esophagus | ESCC | 6.16e-11 | 3.04e-01 | 0.1617 |
| 10621 | POLR3F | P22T-E | Human | Esophagus | ESCC | 1.01e-09 | 1.32e-01 | 0.1236 |
| 10621 | POLR3F | P23T-E | Human | Esophagus | ESCC | 1.42e-11 | 3.68e-01 | 0.108 |
| 10621 | POLR3F | P24T-E | Human | Esophagus | ESCC | 1.32e-08 | 1.65e-01 | 0.1287 |
| 10621 | POLR3F | P26T-E | Human | Esophagus | ESCC | 1.49e-22 | 2.79e-01 | 0.1276 |
| 10621 | POLR3F | P27T-E | Human | Esophagus | ESCC | 1.15e-10 | 1.15e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:00063833 | Esophagus | ESCC | transcription by RNA polymerase III | 41/8552 | 46/18723 | 7.69e-10 | 1.90e-08 | 41 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:003248112 | Esophagus | ESCC | positive regulation of type I interferon production | 42/8552 | 58/18723 | 3.27e-05 | 2.70e-04 | 42 |
| GO:00326084 | Esophagus | ESCC | interferon-beta production | 40/8552 | 56/18723 | 8.36e-05 | 6.08e-04 | 40 |
| GO:00326484 | Esophagus | ESCC | regulation of interferon-beta production | 40/8552 | 56/18723 | 8.36e-05 | 6.08e-04 | 40 |
| GO:0006359 | Esophagus | ESCC | regulation of transcription by RNA polymerase III | 19/8552 | 22/18723 | 9.52e-05 | 6.78e-04 | 19 |
| GO:003247912 | Esophagus | ESCC | regulation of type I interferon production | 61/8552 | 95/18723 | 2.05e-04 | 1.29e-03 | 61 |
| GO:003260612 | Esophagus | ESCC | type I interferon production | 61/8552 | 95/18723 | 2.05e-04 | 1.29e-03 | 61 |
| GO:00327284 | Esophagus | ESCC | positive regulation of interferon-beta production | 29/8552 | 39/18723 | 2.59e-04 | 1.58e-03 | 29 |
| GO:00450885 | Esophagus | ESCC | regulation of innate immune response | 125/8552 | 218/18723 | 3.34e-04 | 1.96e-03 | 125 |
| GO:000181916 | Esophagus | ESCC | positive regulation of cytokine production | 244/8552 | 467/18723 | 2.29e-03 | 1.01e-02 | 244 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:00028317 | Oral cavity | OSCC | regulation of response to biotic stimulus | 177/7305 | 327/18723 | 1.73e-08 | 3.43e-07 | 177 |
| GO:00063832 | Oral cavity | OSCC | transcription by RNA polymerase III | 34/7305 | 46/18723 | 1.61e-06 | 2.11e-05 | 34 |
| GO:00450884 | Oral cavity | OSCC | regulation of innate immune response | 116/7305 | 218/18723 | 1.36e-05 | 1.37e-04 | 116 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0302021 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa046234 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0302031 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa0462311 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa030204 | Oral cavity | OSCC | RNA polymerase | 25/3704 | 34/8465 | 4.12e-04 | 1.27e-03 | 6.45e-04 | 25 |
| hsa04623 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
| hsa0302011 | Oral cavity | OSCC | RNA polymerase | 25/3704 | 34/8465 | 4.12e-04 | 1.27e-03 | 6.45e-04 | 25 |
| hsa046231 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| POLR3F | SNV | Missense_Mutation | rs749735863 | c.587N>A | p.Arg196Gln | p.R196Q | Q9H1D9 | protein_coding | tolerated(0.39) | benign(0.031) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| POLR3F | SNV | Missense_Mutation | c.532N>C | p.Glu178Gln | p.E178Q | Q9H1D9 | protein_coding | deleterious(0.01) | benign(0.354) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| POLR3F | deletion | Frame_Shift_Del | c.810delC | p.Tyr270Ter | p.Y270* | Q9H1D9 | protein_coding | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |||
| POLR3F | SNV | Missense_Mutation | c.408N>G | p.Ile136Met | p.I136M | Q9H1D9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1MI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| POLR3F | SNV | Missense_Mutation | c.718N>C | p.Asn240His | p.N240H | Q9H1D9 | protein_coding | deleterious(0.02) | probably_damaging(0.927) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| POLR3F | SNV | Missense_Mutation | c.515N>A | p.Phe172Tyr | p.F172Y | Q9H1D9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| POLR3F | SNV | Missense_Mutation | c.305N>A | p.Ala102Glu | p.A102E | Q9H1D9 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
| POLR3F | SNV | Missense_Mutation | novel | c.384G>T | p.Lys128Asn | p.K128N | Q9H1D9 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| POLR3F | SNV | Missense_Mutation | rs780275934 | c.752N>T | p.Thr251Met | p.T251M | Q9H1D9 | protein_coding | deleterious(0.01) | possibly_damaging(0.488) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| POLR3F | SNV | Missense_Mutation | novel | c.801N>T | p.Met267Ile | p.M267I | Q9H1D9 | protein_coding | tolerated(0.57) | benign(0) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |